This report is unexpected, since TNF inhibitors have proven efficacy for the treatment of both RA and psoriasis. Each of the nine patients had a definite diagnosis of RA; eight were positive for ...

The use of IL-17 inhibitors in patients with psoriasis was associated with an increased risk for fungal infections when compared with other biologics.

Tumour Necrosis Factor TNF is crucial for defence but can drive chronic inflammation linked to arthritis and autoimmune diseases when overproduced ...

Adalimumab was the third TNF inhibitor to be approved for psoriasis, but has been gaining momentum in the market against etanercept, owing to superior efficacy data from clinical trials (Psoriasis ...

such as TNF alpha inhibitors, IL-17 inhibitors, and IL-23 inhibitors. With inverse psoriasis, people develop smooth, shiny lesions in body folds. On skin of color the lesions may be purplish ...

TNF is considered to be an important pro-inflammatory ... In patients suffering from extensive plaque psoriasis, ETA is usually initiated with 2 × 50 mg weekly in order to achieve a fast response.

Once again, its effect on axial disease, psoriasis, dactylitis and enthesitis ... to ensure equivalent efficacy and safety to existing TNF inhibitors. Licencing these agents should allow patients ...

Investigators aimed to highlight aspects that may predict the time to relapse among patients with psoriasis who discontinued use of biologic therapy.

Not everyone with psoriasis develops psoriatic arthritis ... “The initial treatments are the same for both,” says Bauer, noting that tumor necrosis factor (TNF) inhibitors work well for both types of ...

High threshold clinical responses (Investigator’s Global Assessment Score 0 or 1, and Psoriasis Area and Severity Index ... while IZAR-2 will enroll patients with an inadequate response to tumor ...

Nail psoriasis can make it hard to do certain tasks that involve the fingernails, like grasping small objects. Intact fingernails and toenails also help to protect the fingers and toes ...

Innovent Biologics (IVBXF) announced the latest clinical results of a multicenter, open-label Phase 2 study of picankibart, a recombinant ...